Pen needles are an integral part of the diabetes treatment experience for patients who rely on injectable therapies. Nearly 30 years ago, Novo Nordisk launched the world's first pen needle. Since then, we have strived to improve the injection experience for patients by developing progressively shorter and thinner needles. NovoFine® Plus, the company’s newest needle, is our shortest at 4 mm and features many improvements that are designed to make injections more comfortable. Learn more about the Novo Nordisk family of pen needles below.

**NovoFine® Plus** is the latest needle advancement from Novo Nordisk. It is a 32G, 4 mm pen needle that uses universal threading, allowing use with major insulin pens. The ultra-short and ultra-thin 32G 4 mm needle is designed for less pain. It has a design that makes it strong, and reduces the risk of bending or breaking.

**NovoFine® 32G Tip** is a universal pen needle, which was launched 6 years ago. Before NovoFine® Plus, it was the latest Novo Nordisk innovation in creating shorter and thinner needles.

**NovoTwist® 32G Tip** was designed exclusively for Novo Nordisk pens. NovoTwist® uses a 32G, 5 mm needle and the simple “twist and click” attachment is an innovative feature among pen needles.

**NovoFine® Autocover® 30G** is a needle with a safety shield designed for use in institutions. The automatic shield feature locks into place, concealing the needle both before and immediately after use, helping to prevent accidental needle-stick injuries.

**References**

2. Data on file. Novo Nordisk; Plainsboro, NJ.